Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

689
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
689
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.2K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Azilsartan medoxomil.

Profiles of drug substances, excipients, and related methodology·2020
Same author

Emtricitabine.

Profiles of drug substances, excipients, and related methodology·2020
Same author

Olmesartan.

Profiles of drug substances, excipients, and related methodology·2017
Same author

Propranolol.

Profiles of drug substances, excipients, and related methodology·2017
Same author

Telmisartan.

Profiles of drug substances, excipients, and related methodology·2015
Same author

Azithromycin.

Profiles of drug substances, excipients, and related methodology·2014

Related Experiment Video

Updated: Apr 30, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

1.1K

Imatinib mesylate.

Badraddin M H Al-Hadiya1, Ahmed H H Bakheit1, Ahmed A Abd-Elgalil2

  • 1Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

Profiles of Drug Substances, Excipients, and Related Methodology
|May 6, 2014
PubMed
Summary
This summary is machine-generated.

Imatinib is a targeted therapy tyrosine kinase inhibitor, effective against Philadelphia chromosome-positive chronic myelogenous leukemia. This study details its properties, analysis, and stability, confirming formulation stability and identifying degradation pathways.

Keywords:
BackgroundCancer drugClinical ApplicationsComprehensive profileImatinib mesylateInteractionsPharmacology

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.5K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

2.3K

Related Experiment Videos

Last Updated: Apr 30, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

1.1K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.5K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

2.3K

Area of Science:

  • Oncology
  • Pharmacology
  • Analytical Chemistry

Background:

  • Imatinib is a tyrosine kinase inhibitor approved for treating Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia and other cancers.
  • It represents a paradigm in targeted cancer therapy by selectively targeting cancer cells.
  • Understanding its comprehensive profile is crucial for its therapeutic application and further research.

Purpose of the Study:

  • To provide a comprehensive profile of imatinib, encompassing its chemical and physical properties.
  • To detail various analytical methods for imatinib assessment.
  • To investigate the stability and degradation pathways of imatinib and its formulations.

Main Methods:

  • Physico-chemical characterization and methods of preparation.
  • Analysis using compendial, electrochemical, spectroscopic (UV/vis, vibrational, NMR, mass spectrometry), and chromatographic techniques (electrophoresis, TLC, HPLC).
  • Stability studies under various conditions (temperature, oxidative, acidic, alkaline) to identify degradation products.

Main Results:

  • Detailed nomenclature, formulae, and physico-chemical properties were established.
  • Multiple analytical methods were validated for imatinib quantification and characterization.
  • Imatinib formulations demonstrated stability at tested temperatures, with identified degradation products under stress conditions.

Conclusions:

  • This study provides a thorough characterization of imatinib, essential for its clinical use and quality control.
  • The established analytical methods ensure reliable assessment of imatinib.
  • Understanding degradation pathways aids in optimizing storage and formulation for enhanced therapeutic efficacy.